Sign up for our monthly newsletter!
Get the latest information and inspirational stories for caregivers, delivered directly to your inbox.
There are now two impressive possible treatments for this form of dementia. But concerns remain over cost and potential side-effects. A new drug, called donanemab, showed promising results in phase-3 trials at slowing down the decline in cognitive functions and reducing the deterioration in the ability to undertake daily tasks independently.See full story at The Guardian